A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Case Medical Research ◽

10.31525/ct1-nct04243785 ◽

2020 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Refractory Acute Myeloid Leukemia ◽

Download Full-text

Dose-enhanced combined priming regimens for refractory acute myeloid leukemia and middle-and-high-risk myelodysplastic syndrome: a single-center, retrospective cohort study

OncoTargets and Therapy ◽

10.2147/ott.s96427 ◽

2016 ◽

pp. 3661 ◽

Author(s):

Xiaorong Ma ◽

Jin Wang ◽

Yan Xu ◽

Wanggang Zhang ◽

Jie Liu ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Cohort Study ◽

High Risk ◽

Myelodysplastic Syndrome ◽

Retrospective Cohort Study ◽

Myeloid Leukemia ◽

Retrospective Cohort ◽

Single Center ◽

Refractory Acute Myeloid Leukemia ◽

Download Full-text

A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome

American Journal of Hematology ◽

10.1002/ajh.25958 ◽

2020 ◽

Vol 95 (12) ◽

pp. 1457-1465

Author(s):

Caner Saygin ◽

Karilyn Larkin ◽

James S. Blachly ◽

Shelley Orwick ◽

Apollinaire Ngankeu ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myelodysplastic Syndrome ◽

Phase I ◽

Myeloid Leukemia ◽

Phase I Study ◽

Refractory Acute Myeloid Leukemia ◽

Download Full-text

Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome

Cancer ◽

10.1002/cncr.31398 ◽

2018 ◽

Vol 124 (13) ◽

pp. 2758-2765 ◽

Author(s):

Rita Assi ◽

Hagop M. Kantarjian ◽

Tapan M. Kadia ◽

Naveen Pemmaraju ◽

Elias Jabbour ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Phase 2 ◽

Open Label Study ◽

Label Study ◽

Refractory Acute Myeloid Leukemia ◽

Download Full-text

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Case Medical Research ◽

10.31525/ct1-nct04047641 ◽

2019 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Newly Diagnosed ◽

Refractory Acute Myeloid Leukemia ◽

Download Full-text

Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome

Annals of Hematology ◽

10.1007/s00277-020-04291-0 ◽

2020 ◽

Author(s):

Márcio Tavares ◽

Sérgio Chacim ◽

José Mário Mariz

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Low Dose ◽

Compassionate Use ◽

Refractory Acute Myeloid Leukemia ◽

Low Dose Cytarabine ◽

Download Full-text

Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2012.03.003 ◽

2012 ◽

Vol 12 (4) ◽

pp. 244-251 ◽

Author(s):

Elias Jabbour ◽

Guillermo Garcia-Manero ◽

Jorge Cortes ◽

Farhad Ravandi ◽

William Plunkett ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Chronic Myeloid Leukemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Blast Phase ◽

Refractory Acute Myeloid Leukemia ◽

Download Full-text

Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome: Bursa Uludag University Experience

Turkish Journal of Internal Medicine ◽

10.46310/tjim.877068 ◽

2021 ◽

Author(s):

İbrahim Ethem PINAR ◽

Fahir ÖZKALEMKAŞ ◽

Vildan OZKOCAMAN ◽

Tuba ERSAL ◽

Cumali YALÇIN ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Refractory Acute Myeloid Leukemia ◽

University Experience ◽

Download Full-text

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Case Medical Research ◽

10.31525/ct1-nct03940352 ◽

2019 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Download Full-text

Faculty Opinions recommendation of Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.10197.467594 ◽

2006 ◽

Author(s):

Mayumi Mori

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Prognostic Models ◽

Intensive Chemotherapy ◽

Download Full-text

Faculty Opinions recommendation of A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1119427.575617 ◽

2008 ◽

Author(s):

Arati Rao

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Low Dose ◽

Randomized Study ◽

Line Therapy ◽

Low Dose Cytarabine ◽

Download Full-text